Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a sixteen-week interval between doses

Tauzin, A.; Gong, S. Y.; Beaudoin-Bussieres, G.; Vezina, D.; Gasser, R.; Nault, L.; Marchitto, L.; Benlarbi, M.; Chatterjee, D.; Nayrac, M.; Laumaea, A.; Prevost, J.; Boutin, M.; Sannier, G.; Nicolas, A.; Bourassa, C.; Gendron-Lepage, G.; Medjahed, H.; Goyette, G.; Bo, Y.; Perreault, J.; Gokool, L.; Morrisseau, C.; Arlotto, P.; Bazin, R.; Dube, M.; De Serres, G.; Brousseau, N.; Richard, J.; Rovito, R.; Cote, M.; Tremblay, C.; Marchetti, G. C.; Duerr, R.; Martel-Laferriere, V.; Kaufmann, D. E.; Finzi, A.

While the standard regimen of the BNT162b2 mRNA vaccine includes two doses administered three weeks apart, some public health authorities decided to space them, raising concerns about vaccine efficacy. Here, we analyzed longitudinal humoral responses including antibody binding, Fc-mediated effector functions and neutralizing activity against the D614G strain but also variants of concern and SARS-CoV-1 in a cohort of SARS-CoV-2 naive and previously infected individuals, with an interval of sixteen weeks between the two doses. While the administration of a second dose to previously infected individuals did not significantly improve humoral responses, we observed a significant increase of humoral responses in naive individuals after the 16-weeks delayed second shot, achieving similar levels as in previously infected individuals. Our results highlight strong vaccine-elicited humoral responses with an extended interval BNT162b2 vaccination for naive individuals.